|
Basal cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
|
31174203 |
2019 |
|
Basal Cell Neoplasm
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
|
31174203 |
2019 |
|
Basal Cell Cancer
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
|
31174203 |
2019 |
|
Basal cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma.
|
27539887 |
2016 |
|
Basal Cell Neoplasm
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma.
|
27539887 |
2016 |
|
Basal Cell Cancer
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma.
|
27539887 |
2016 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Regulator of chromosome condensation 2 (RCC2) is a regulator of cell-cycle progression linked in multiple cancers to pro-tumorigenic phenomena including promotion of tumor growth, tumor metastases and poorer patient prognoses.
|
31277942 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Via shRNA inhibition, we determined that RCC2 is essential to tumor proliferation and tumorigenicity in vitro and in vivo.
|
31277942 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
Particularly, 11 proteins involved in tumor proliferation (MCM2, 4, 6, 7, and MSH2), metastasis (RCC2, CORO1C, CHD4, and IPO9), and cancer metabolism (PHGDH and TYMP) are identified as SCLC-specific proteins.
|
29888431 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
RCC2 physically interacts and deactivates a small GTPase Rac1 that is known to be involved in metastasis.
|
28869598 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Because chemotherapeutic drugs can kill tumor cells by activating Rac1/JNK pathway, we suspect that tumors with RCC2 overexpression would be more resistant to these drugs.
|
29321004 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In addition, RCC2 was able to activate JNK, while inhibition of JNK suppressed the effect of RCC2 on LUAD cell migration, invasion, EMT, and the expression of MMP-2 and MMP-9.<b>Conclusions:</b> RCC2 plays a pivotal role in LUAD metastasis by inducing EMT via activation of MAPK-JNK signaling.<i></i>.
|
28606921 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Importantly, increased level of RCC2 was significantly associated with T status of tumor (<i>P</i> = 0.002), lymph node metastasis (<i>P</i> = 0.004), and advanced clinical stage (<i>P</i> = 0.001).
|
28606921 |
2017 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
High-risk patients with either MSI or MSS tumors can be identified with cost-effective routine RCC2 assays.
|
25910952 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
|
30768358 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
Luciferase assays were used to demonstrate that RCC2 was a directed target of miR-331-3p in EOC.
|
31749881 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We propose that the p53/RCC2/Rac1 axis is a potential target for cancer therapy.
|
28869598 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Three cancer cell lines with up- or down-regulation of RCC2 were used to evaluate cell proliferation, apoptosis, Rac1 signaling and sensitivity to a group of nine chemotherapeutic drugs.
|
29321004 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Three cancer cell lines with up- or down-regulation of RCC2 were used to evaluate cell proliferation, apoptosis, Rac1 signaling and sensitivity to a group of nine chemotherapeutic drugs.
|
29321004 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
We propose that the p53/RCC2/Rac1 axis is a potential target for cancer therapy.
|
28869598 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In an immunohistochemistry evaluation of tissue microarray, RCC2 was over-expressed in 88.3% of primary lung cancer and 65.2% of ovarian cancer as compared to non-neoplastic lung and ovarian tissues, respectively.
|
29321004 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In addition, RCC2 was able to activate JNK, while inhibition of JNK suppressed the effect of RCC2 on LUAD cell migration, invasion, EMT, and the expression of MMP-2 and MMP-9.<b>Conclusions:</b> RCC2 plays a pivotal role in LUAD metastasis by inducing EMT via activation of MAPK-JNK signaling.<i>Clin Cancer Res; 23(18); 5598-610.©2017 AACR</i>.
|
28606921 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In addition, RCC2 was able to activate JNK, while inhibition of JNK suppressed the effect of RCC2 on LUAD cell migration, invasion, EMT, and the expression of MMP-2 and MMP-9.<b>Conclusions:</b> RCC2 plays a pivotal role in LUAD metastasis by inducing EMT via activation of MAPK-JNK signaling.<i>Clin Cancer Res; 23(18); 5598-610.©2017 AACR</i>.
|
28606921 |
2017 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
|
30768358 |
2019 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
|
30768358 |
2019 |